Maycon schreef op 9 november 2021 13:24:
GLPG3667 Presentation at ACR21 Nov 8th, 2021
Dear investor,
Yesterday (Monday Nov 8th), the Galapagos team gave an oral presentation on our TYK2 program with GLPG3667 at the American Congress of Rheumatology (ACR21). Please find below a short summary of the presentation (PDF available upon request).
Pharmacological characterization of GLPG3667, a selective TYK2 inhibitor for treatment of inflammatory diseases.
Presented by René Galien. Session: Cytokines & cell trafficking, November 8th 2021, 2:45-3:00PM ET
The presentation gives information on the potency and selectivity of our GLPG3667 TYK2 compound and proof of pharmacological activity in a psoriasis mouse model (IL-23 driven), further supported by human healthy volunteer data. The data demonstrate that in human fresh blood cells, GLPG3667 displays selectivity for TYK2-dependent pathways toward JAK1- and JAK2-dependent pathways. This was confirmed in healthy volunteers dosed orally with GLPG3667 during a Phase 1 study. In the dermal ear inflammation psoriasis model, activity was shown with minimal effective once-daily oral dosing of 3 mg/kg. Further evidence came from healthy volunteer blood sample data post in vivo IFNa challenge, showing that GLPG3667 completely inhibited IFN-response gene signature. In conclusion, these data point to GLPG3667 as a selective TYK2 inhibitor with demonstrated activity in vivo, supporting its clinical development in inflammatory indications.
acrabstracts.org/abstract/pharmacolog... Kind regards,
The Galapagos IR team
ir@glpg.com